Northeastern U.S. Children Show Signs of Worse Asthma in Wildfire Smoke
December 12, 2025
Brand Name :
TicoVac
Synonyms :
tick-borne encephalitis vaccine
Class :
Vaccines, Inactivated, Viral
Dosage Forms & StrengthsÂ
Suspension Â
0.25ml prefilled syringeÂ
0.5ml prefilled syringeÂ
Administer dose of 0.5 ml intramuscularly, then repeat again for 2 weeks to 3 months after first dose and then for 5 to 12 months after second dose
Dosage Forms & StrengthsÂ
Suspension Â
0.25ml prefilled syringeÂ
0.5ml prefilled syringeÂ
For <1 year old: Safety and efficacy not determined
For 1 to 15 years old:
Administer dose of 0.25 ml via intramuscularly then repeat for 1 to 3 months after first dose and for 5 to 12 months after second dose
For ≥16 years old:
Administer dose of 0.5 ml intramuscularly, then repeat again for 2 weeks to 3 months after first dose and then for 5 to 12 months after second dose
Refer to adult dosingÂ
the therapeutic activity of the tick-borne encephalitis vaccine (whole virus, inactivated) may be reduced
Actions and SpectrumÂ
Inactivated vaccines contain killed virus particles and viral proteins. When the vaccine is administered, it stimulates the immune system to recognize these viral components as foreign and mount an immune response.
Frequency defined Â
>10%Â
Injection site tenderness Â
Local painÂ
Headache Â
Local pain Â
Injection site tenderness Â
1-10%Â
Muscle painÂ
Fatigue Â
Headache Â
Fever Â
Restlessness Â
Post marketing ReportsÂ
HypersensitivityÂ
Visual impairmentÂ
Herpes zoster Â
Anaphylactic reactionÂ
PhotophobiaÂ
TachycardiaÂ
Eye painÂ
TinnitusÂ
Black Box WarningÂ
NoneÂ
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy consideration:Â
Pregnancy category: N/AÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology Â
When the inactivated vaccine is administered, it triggers the immune system to recognize the viral components as foreign. This recognition leads to the production of antibodies specific to the tick-borne encephalitis virus.Â
PharmacodynamicsÂ
Tick-borne encephalitis vaccination is the production of antibodies, which are proteins that can specifically recognize and neutralize the tick-borne encephalitis virus.Â
PharmacokineticsÂ
Limited information available on ADME.Â
AdministrationÂ
Tick-borne encephalitis vaccine is administered via intramuscularly in suspension form.
Patient information leafletÂ
Generic Name: tick-borne encephalitis vaccineÂ
Why do we use tick-borne encephalitis vaccine?Â
The tick-borne encephalitis vaccine indicated in the prevention of tick-borne encephalitis. Â
The vaccine helps reduce the risk of contracting the virus and developing the associated neurological complications.Â